AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Job Trends

Top 12 Life Sciences Companies Hiring Now in 2019

It’s a new year! Is one of your New Year’s resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!

January 4, 2019

1 min read

Editorial Staff

Business

AbbVie Strikes Deal With Lupin for Blood Cancer Program

AbbVie closed out 2018 by striking a nearly $1 billion licensing deal for India-based Lupin Limited’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.

January 2, 2019

2 min read

Alex Keown

Business

AbbVie Strategically Restructures Executive Leadership Team

The new structure creates four top managers who will report directly to the company CEO. All other executives will report to those managers.

December 18, 2018

2 min read

Alex Keown

Drug Development

Eli Lilly’s Taltz Stands up to Humira in Psoriatic Arthritis Patients

At 24 weeks, the study met its primary endpoint. Lilly’s Taltz demonstrated superiority against AbbVie’s Humira, the best-selling drug in the world, in improving the signs and symptoms of active PsA.

December 17, 2018

2 min read

Alex Keown

Pharm Country

Readers’ Picks: Top 10 Stories of 2018

As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.

December 13, 2018

5 min read

Mark Terry

BioMidwest

Big Drug Launches Have Taught Drug Companies Some Important Lessons

With the closure of another year just weeks ahead, this time of year is one that many people use to take a look behind and see what lessons were learned over the past 12 months. For the world of biopharma, it’s also important to see what lessons have been learned.

December 11, 2018

3 min read

Alex Keown

Top 12 Life Sciences Companies Hiring Now for Candidates Like You

Winter and the Holidays are right around the corner, but don’t stop your job search! Check out the top companies who are looking for candidates like you right now!

December 7, 2018

1 min read

Editorial Staff

BioMidwest

AbbVie Continues Charitable Giving, Donates $50 Million to St. Jude

Christmas came a little early for St. Jude Children’s Research Hospital in the form of a $50 million contribution from pharma giant AbbVie – the largest single contribution made to the famed hospital.

December 7, 2018

3 min read

Alex Keown

Drug Development

AbbVie’s Rova-T Sees Another Failure, Casts Doubt on Multi-Billion-Dollar Acquisition

Illinois-based AbbVie halted a Phase III trial evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.

December 6, 2018

2 min read

Alex Keown

JOBS